once monthly glp-1 agonist Injections of an ultra-long-acting investigational led to significant weight loss in people with overweight or obesity, with reductions continuing after a switch to once-monthly dosing, according to the ongoing VESPER Understanding GLP-1 receptor agonists and

find a lower risk of developing vascular dementia in patients with established gout (Hong et al., 2015)

Reduces the appearance of cellulite and scars

(6), although there were no statistically significant differences between the UA group (1,000 mg/day) and the control group in peak oxygen uptake and performance on the 6-min walk test (6MWT), the UA group showed significant improvements compared to their own baseline

Persistent inflammation and chronic oxidative stress are risk factors for many cancer types, and both of these issues can be deferred by a dietary intake of anti-inflammatory and antioxidant nutrients